Singapore, Feb. 20 -- Japan headquartered Astellas Pharma and US-based biotech startup Kelonia Therapeutics have announced a collaborative effort between Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas) and Kelonia to develop innovative immuno-oncology therapeutics.

Kelonia specialises in genetic medicines using its in vivo gene placement system called iGPS, which efficiently delivers genetic cargo to target cells within the patient's body. Xyphos possesses a proprietary technology platform called ACCEL, which involves its convertibleCAR technology on immune cells.

Under the agreement, the companies will combine Kelonia's iGPS with Xyphos' ACCEL technology to develop novel in vivo CAR-T Cell therapies targeting up to two...